DAM
CUE icon

Doheny Asset Management’s Cue Biopharma CUE Stock Holding History

Doheny Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-425
Closed -$156K – 99
2021
Q1 		$156K Buy
425
+20
+5% +$8.23K 0.11% 101
2020
Q4 		$152K Sell
405
-72
-15% -$28.8K 0.11% 97
2020
Q3 		$215K Buy
477
+55
+13% +$31.7K 0.18% 90
2020
Q2 		$310K Buy
422
+17
+4% +$12.3K 0.29% 69
2020
Q1 		$193K Hold
405
– – 0.15% 94
2019
Q4 		$193K Buy
+405
New +$127K 0.15% 94

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Doheny Asset Management's CUE Position: Q2 2021 in Review

Doheny Asset Management sold out of Cue Biopharma (CUE) in Q2 2021, closing a stake of 425 shares — an estimated $156K sold.

Doheny Asset Management first reported a position in CUE in Q4 2019 and held it in 6 quarters. The position peaked at $310K in Q2 2020. 89 funds tracked by Wall St. Rank hold CUE as of Q2 2021.

  • Doheny Asset Management reported no remaining Cue Biopharma position as of Q2 2021 after selling out during the quarter.
  • Doheny Asset Management sold 425 Cue Biopharma shares in Q2 2021, an estimated $156K.
  • Doheny Asset Management first reported a position in Cue Biopharma in Q4 2019 and held it in 6 quarters.
  • Doheny Asset Management's Cue Biopharma position peaked at $310K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2021.

Based on Doheny Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.